Kezar Life Sciences Inc. (KZR)
6.21
-0.09 (-1.43%)
At close: Jan 14, 2025, 3:59 PM
6.21
-0.08%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 6.21 |
| Market Cap | 45.35M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -13.12 |
| PE Ratio (ttm) | -0.47 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 7.05 |
| Volume | 55,486 |
| Avg. Volume (20D) | 56,208 |
| Open | 6.35 |
| Previous Close | 6.30 |
| Day's Range | 6.21 - 6.38 |
| 52-Week Range | 5.20 - 11.40 |
| Beta | undefined |
About KZR
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2018
Employees 58
Stock Exchange NASDAQ
Ticker Symbol KZR
Analyst Forecast
According to 2 analyst ratings, the average rating for KZR stock is "Hold." The 12-month stock price forecast is $9, which is an increase of 44.81% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
Next Earnings Release
Kezar Life Sciences Inc. is scheduled to release its earnings on Mar 13, 2025,
during market hours.
Analysts project revenue of $1.60M, reflecting a n/a YoY growth and earnings per share of -3.3, making a -25.00% decrease YoY.
Analysts project revenue of $1.60M, reflecting a n/a YoY growth and earnings per share of -3.3, making a -25.00% decrease YoY.
3 months ago ·
Source
+42.1%
Kezar Life Sciences shares are trading higher afte...
Unlock content with
Pro Subscription
